Tools to control RhoA signaling in cells
Single-component optogenetic tools to bidirectionally control RhoA in mechanotransduction
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10930814
This study is exploring new ways to control a specific signaling process in cells that helps them respond to physical forces, which could improve our understanding of how cells move and behave, and might lead to better treatments for different health issues.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10930814 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative optogenetic tools that allow for precise control of RhoA signaling in cells, which is crucial for understanding how cells respond to mechanical stimuli. By activating or inactivating RhoA, researchers aim to study its role in actin organization and cellular movement. The project will involve various physiological assays to assess the effectiveness of these tools and their impact on cell behavior. The ultimate goal is to enhance our understanding of cellular mechanotransduction, which could have implications for various medical conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals with conditions that affect cellular movement or mechanotransduction, such as certain cancers or fibrotic diseases.
Not a fit: Patients with conditions unrelated to cellular signaling or mechanotransduction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights into cellular behavior and potentially inform treatments for conditions related to cell movement and mechanotransduction.
How similar studies have performed: Other research has shown success with optogenetic approaches in controlling cellular processes, indicating that this methodology is promising and has been validated in related studies.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOERCKEL, JOEL D — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: BOERCKEL, JOEL D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.